investorscraft@gmail.com

Intrinsic Value of Calliditas Therapeutics AB Sponsored ADR (CALT)

Previous Close$20.04
Intrinsic Value
Upside potential
Previous Close
$20.04

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2022-12-31 and quarterly data as of 2023-09-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %197.5NaN
Revenue, $80NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m121NaN
Operating income, $m-42NaN
EBITDA, $m-41NaN
Interest expense (income), $mNaN
Earnings before tax, $m-41NaN
Tax expense, $m0NaN
Net income, $m-41NaN

BALANCE SHEET

Cash and short-term investments, $m124NaN
Total assets, $m194NaN
Adjusted assets (=assets-cash), $m70NaN
Average production assets, $m48NaN
Working capital, $m108NaN
Total debt, $m73NaN
Total liabilities, $m118NaN
Total equity, $m76NaN
Debt-to-equity ratio0.964NaN
Adjusted equity ratio-0.672NaN

CASH FLOW

Net income, $m-41NaN
Depreciation, amort., depletion, $m1NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-31NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-0NaN
Free cash flow, $m-31NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m108
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount